Global Ophthalmology and Glaucoma Conference

Glaucoma is being considered as a second leading cause of blindness in the world and is responsible 12.5% of total blindness. It is a neurodegenerative disease where ganglionic cell become degenerated progressively leading to blindness. Due to lack of proper treatment blindness which occurs is irreversible. Though increased intraocular pressure is the major risk factor to cause damage yet glutamate, nitric oxide, vascular supply can also be considered as other risk factors.

 

In POAG to maintain the baseline level of IOP to reduce the extent of damage we can do medical, laser or surgical treatment. to with to reduce the mechanical effect over the nerve To reduce IOP, vascular damage, and biochemical effect. Medical therapy is the initial treatment to start. There are different line of treatment. Even we can use single or multiple drug depending on IOP. PG analog, Alpha agonist , beta blocker are most widely used. Along with this newer drug are also being introduced eg Tufluprost .But whatever we use it should be effective, tolerable, and affordable. Future upcoming anti glaucoma drug will not only reduce IOP but also protect trabecular meshwork, improve blood flow to optic nerve head, and slower the progress of damage.

 

Key word: PG analog, Alpha agonist, IOP, Tufluprost

 

Disclosure: The authors have no conflicts of interest to declare.